Provided by Tiger Trade Technology Pte. Ltd.

LivaNova PLC

66.56
+1.532.35%
Post-market: 66.560.00000.00%18:17 EST
Volume:578.05K
Turnover:38.40M
Market Cap:3.63B
PE:-16.68
High:66.92
Open:65.45
Low:64.98
Close:65.03
52wk High:67.92
52wk Low:32.48
Shares:54.61M
Float Shares:54.41M
Volume Ratio:0.66
T/O Rate:1.06%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.9912
EPS(LYR):1.16
ROE:-17.63%
ROA:5.24%
PB:3.14
PE(LYR):57.38

Loading ...

A Look At LivaNova (LIVN) Valuation After KeyBanc Upgrade And Renewed Medtech Optimism

Simply Wall St.
·
Feb 03

Analysts Offer Insights on Healthcare Companies: Nektar Therapeutics (NKTR) and LivaNova (LIVN)

TIPRANKS
·
Jan 26

LivaNova plc to Announce Fourth-Quarter and Full-Year Results

Reuters
·
Jan 20

LivaNova to Announce Fourth-Quarter and Full-Year 2025 Results

THOMSON REUTERS
·
Jan 20

LivaNova Chief Legal Officer Michael Hutchinson Resigns

Reuters
·
Jan 14

LivaNova (LIVN) Is Up 6.2% After Fresh Analyst Optimism on Advanced Therapies Portfolio - What's Changed

Simply Wall St.
·
Jan 11

LivaNova Is Maintained at Equal-Weight by Barclays

Dow Jones
·
Jan 09

LivaNova price target raised to $66 from $56 at Goldman Sachs

TIPRANKS
·
Jan 09

Barclays Reaffirms Their Hold Rating on LivaNova (LIVN)

TIPRANKS
·
Jan 09

LivaNova (LIVN): Reassessing Valuation After KeyBanc’s Overweight Initiation and Growth Outlook

Simply Wall St.
·
Dec 22, 2025

KeyBanc Initiates LivaNova at Overweight With $81 Price Target

MT Newswires Live
·
Dec 19, 2025

LivaNova Initiated at Overweight by Keybanc

Dow Jones
·
Dec 19, 2025

LivaNova Plc : Keybanc Initiates Coverage With Overweight Rating and Target Price $81

THOMSON REUTERS
·
Dec 19, 2025

Assessing LivaNova (LIVN)’s Valuation After Hiring ResMed Veteran to Lead Sleep Apnea Commercialization

Simply Wall St.
·
Dec 15, 2025

The Bull Case For LivaNova (LIVN) Could Change Following Medicare VNS Boost And New OSA Leader

Simply Wall St.
·
Dec 09, 2025

LivaNova Highlights CORE-VNS Study Showing VNS Therapy Reduces Seizure Frequency and Healthcare Costs in Drug-Resistant Epilepsy

Reuters
·
Dec 03, 2025

LivaNova Names Lucile Blaise Global Head of Commercialization for Obstructive Sleep Apnea

Reuters
·
Dec 02, 2025

LivaNova Appoints Lucile Blaise as Global Head of Commercialization, Obstructive Sleep Apnea

THOMSON REUTERS
·
Dec 02, 2025

LivaNova CFO to Present Business Update at Piper Sandler Healthcare Conference

Reuters
·
Nov 25, 2025

LivaNova Shares Hit 52-Week High After VNS Therapy Gets Increased Payment Classification

Dow Jones
·
Nov 24, 2025